HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.

about

Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.

P2860

Q47383689-94D6487D-F433-426D-ADD3-D2F25563ABC1

P2860

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.

Item

http://www.wikidata.org/entity/Q40152011

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

HIV-1 gp41-targeting fusion in ...... inactivation of HIV-1 virions.

@en

type

Item

label

HIV-1 gp41-targeting fusion in ...... inactivation of HIV-1 virions.

@en

prefLabel

HIV-1 gp41-targeting fusion in ...... inactivation of HIV-1 virions.

@en

P1476

HIV-1 gp41-targeting fusion in ...... inactivation of HIV-1 virions.

@en

P2093

Dimiter S Dimitrov

http://www.w3.org/2001/XMLSchema#string

Lu Lu

http://www.w3.org/2001/XMLSchema#string

Qian Wang

http://www.w3.org/2001/XMLSchema#string

Qianqian Qi

http://www.w3.org/2001/XMLSchema#string

Weizao Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120

Core structure of gp41 from the HIV envelope glycoprotein

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

HIV entry and its inhibition

The antigenic structure of the HIV gp120 envelope glycoprotein

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Spectroscopic determination of tryptophan and tyrosine in proteins

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

P2888

emi.2017.46

P304

e59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EMI.2017.46

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shibo Jiang

Lanying Du

P577

2017-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086111927

http://www.w3.org/2001/XMLSchema#string

P698

28634358

http://www.w3.org/2001/XMLSchema#string

P932

5520319

http://www.w3.org/2001/XMLSchema#string

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.

about

P2860

P2860

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932